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ex vivo monocyte chemotaxis to VEGF-A and MCP-1 [4]. Based on
these ﬁndings, we proposed that monocytes can be used as circulating
“biosensors” to detect metabolic deregulation and elevated cardiovas-
cular risk [4]. However, HL often co-exists with other cardiovascular
risk factors such as diabetes mellitus (DM) or smoking, all known to
negatively affect monocyte chemotaxis [4,5].
We now demonstrate that monocytes fromApoE−/−micewith HL
show a completely abrogated chemotaxis towards VEGF-A and a signif-
icantly decreased one towards MCP-1. Experiments were approved by
the local animal ethical committee of Maastricht University. Blood was
sampled [6] and white blood cell counts were performed. Lipid values
were measured enzymatically. Plasma lipid levels were signiﬁcantly el-Hyperlipidemia (HL) is a major cardiovascular risk factor promoting
atherogenesis leading to coronary and peripheral artery disease. Collat-
eral vessel development, a crucial compensatory mechanism in periph-
eral artery disease, is negatively inﬂuenced by HL [1]. Monocytes and
tissue-resident macrophages accelerate both atherogenesis and
arteriogenesis by supplying growth factors, cytokines and proteolytic
enzymes [2]. The decreased monocyte/macrophage accumulation
around growing collateral vessels in HL is associated with jeopardized
arteriogenesis [1].
Ligand-inducedmonocyte extravasation to sites of collateral growth
is a crucial step. This involves several factors including monocyte
chemoattractant protein-1 (MCP-1) and vascular endothelial factor-A
(VEGF-A), which facilitate monocyte chemotaxis in arteriogenesis, a
short lasting and well deﬁned process [2,3]. Previous studies in humansvascular Medicine, Muenster
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evated in ApoE−/−mice (Table 1). ApoE−/−mice had signiﬁcantly
higher numbers of CD11b + monocytes (p b 0.05).
For chemotaxis analysis blood from sex, age and genetically (C57Bl/6
or ApoE−/−) matched mice (avg. 5–6 mice per experimental condi-
tion, each condition was repeated 3–6 times— “n” in Fig. 1) was pooled
and chemotaxis analysis of isolated monocytes was performed [7].
Monocytes from ApoE−/−mice show signiﬁcantly impaired chemo-
tactic responses to VEGF-A and MCP-1 compared to wild-type (WT)
mice (Fig. 1A, B). In fact, chemotaxis to VEGF-A was not distinguishable
from chemokinesis. In contrast, MCP-1-induced chemotaxis was
reduced with only a moderate stimulation at the optimal concentration
of 10 ng/mL (p b 0.05). Furthermore, monocytes from ApoE−/−mice
had a signiﬁcantly elevated chemokinesis (Fig. 1C) as compared to WT
mice (p b 0.05).
The pioneering ﬁnding of this study is that HL-conditioned mono-
cytes from ApoE−/− mice are dysfunctional, as chemotaxis towards
both VEGF-A or MCP-1 is severely impaired. These data imply that i.)
monocytes show a functional defect in the presence of HL, and that ii.)
monocyte dysfunction is likely to contribute to pathological changes
observed in ApoE−/−mice [1].
Besides stimulation of atherogenesis [8], chronic HL impairs
arteriogenesis [1]. Monocytes contribute to arteriogenesis by VEGFR-
1- [4] or CCR-2-mediated [2] migration from the blood stream to the
growing vessel [2]. Reduced expression of arteriogenic factors is an
unlikely cause for impaired arteriogenesis in HL as therapeutic rescue
attempts with either VEGF-A orMCP-1 largely failed [1,9]. Furthermore,
impaired arteriogenesis in HL mice was accompanied by decreasede under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Characteristics of mice, plasma lipid levels and monocyte numbers.
WT (n = 34) ApoE−/−
(n = 34)
p-Value
Age of mice (weeks) 38.9 ± 8.4 37.8 ± 10.1 n.s.
Total cholesterol (mg/dL) 55.07 ± 7.97 399.94 ± 85.8 p b 0.05
LDL cholesterol (mg/dL) 5.92 ± 2.89 278.46 ± 64.29 p b 0.05
HDL cholesterol (mg/dL) 41.37 ± 6.55 98.18 ± 16.24 p b 0.05
Triglicerides (mg/dL) 46.05 ± 12.71 116.53 ± 56.29 p b 0.05
Mononuclear cells (MNC, ×106/mL) 1.47 ± 0.32 1.59 ± 0.47 n.s.
CD11b + monocytes (% of MNC) 6.35 ± 0.86 11.97 ± 2.26* p b 0.05
LDL— low density lipoprotein, HDL— high density lipoprotein.
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ing the arteriogenic stimulation [1]. This previous ﬁnding implies – in
the light of our novel data – that both native as well as growth factor-
stimulated arteriogenesis are reduced in HL due to a reduced/delayed
accumulation of dysfunctional blood-derived monocytes at sites of
vascular repair [1]. Indeed, bone marrow-derived cells from WT mice
alleviate hindlimb ischemia in ApoE−/− mice by improving blood
ﬂow and promoting arteriogenesis [10].
Our previous work on human monocytes documented an impaired
chemotactic response to arteriogenic ligands VEGF-A and MCP-1 [4] in
HL. Our novel ﬁndings proof the same in ApoE−/− mice. Impaired
monocyte chemotaxis to VEGF-A contributes to impaired arteriogenesis
in DM [4]. DM induces unspeciﬁc monocyte activation secondary to in-
creased oxidative stress and advanced glycation of functionally relevant
molecules [5]. The describedmonocyte dysfunction in HLmay be due to
monocyte activation following lipid overload-induced oxidative stress
and leads to up-regulation of adhesion molecules [11]. This activation
of monocytes may explain the observed elevated chemokinesis in
ApoE−/− mice (Fig. 1C) and extravasation to inﬂamed endothelium
of atherosclerotic plaques. Altogether, increased adhesive properties,
increased monocyte numbers (Table 1) and extensive intraplaqueWild-type 
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Fig. 1.Monocyte motility fromWT and ApoE−/−mice to VEGF-A and MCP-1. Chemotactic re
baseline migration (chemokinesis, 3 h) presented as cell number/power ﬁeld (mean ± standar
ability of difference between the groupswas evaluated using Kruskal–Wallis test. Subsequently,
paring corresponding conditions of two mouse phenotypes.angiogenesis will promote atherogenesis by progressive monocyte
migration to the lesion [8] despite partially impaired migration to
pro-atherogenic stimuli (here tested MCP-1). A broad spectrum of
chemokines is responsible for monocyte recruitment in atherosclerosis.
Modiﬁed lipoproteins may serve as chemoattractants [8] as well.
Therefore, therapeutic strategies may need to target multiple targets.
In the process of compensatory arteriogenesis the stimuli for mono-
cyte recruitment and the therapeutic time window (days/weeks) are
rather short compared to atherosclerosis (years/decades) [2]. Therefore
a decreasedmonocyte response demonstrated in our studymay provide
a functional basis for impaired/delayed arteriogenesis while atherogen-
esis continues.
Lowering monocyte numbers can block the progression of athero-
sclerosis [12]. The applicability, however, is limited by the fact that
post-infarctionmonocytosis is physiologically required for both healing
the damaged myocardium [13] and for neovascularisation [2]. These
ﬁndings point towards the dilemma of why and how monocytes pro-
mote tissue healing in infarcted myocardium and in parallel worsen
atherosclerosis. Monocytosis is an accompanying condition featuring
several cardiovascular risk factors (e.g., HL, DM) in which the healing
capability of monocytes is disturbed. Our ﬁndings stress the importance
of therapeutically improving monocyte responsiveness to “healing”
stimuli such as VEGF, which then could allow to therapeutically lower
monocyte counts as a second, independent step.
HLmay have an evenmore detrimental effect on arteriogenesis than
DM [14]. Therefore, it will be of utmost importance to further investi-
gate the mechanisms hampering monocyte chemotaxis in HL. This
should provide important insight into the pathophysiology of HL and
into the basis for therapeutic correction of monocyte function to
improve arteriogenesis in HL. It is tempting to speculate that the
HL-relatedmonocyte defect is different from the DM-related phenotype
as monocyte chemokinesis is signiﬁcantly elevated in HL.
This is the ﬁrst description of monocyte dysfunction in ApoE−/−
mice, namely an impaired chemotactic response. This is likely to explainMCP-1   
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sponse to VEGF-A (A) and MCP-1 (B) presented as percentage of unstimulated control; C,
d error of mean). Statistical analysis was performed using SPSS 18.0.1 software. The prob-
Mann–Whitney testwas performed to estimate the level of signiﬁcance. *— p b 0.05, com-
216 V. Tchaikovski et al. / International Journal of Cardiology 190 (2015) 214–216some of the pathogenetic consequences of HL including the activated
atherogenesis as well as the hampered angiogenesis/arteriogenesis.
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